List view / Grid view
11 November 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor blocker (ARB) has reached 50 million patient-years of real world experience...
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
30 September 2013 | By Boehringer Ingelheim
LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib* provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced today that veterinarians and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumonia...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
19 September 2013 | By Boehringer Ingelheim
Companies collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes...
